GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6340 MR 16728 hydrochlorideSummary: stimulates the release of acetylcholine from synaptosomes -
B6347 Methylergometrine maleateTarget: 5-HT1 Receptor|5-HT2 ReceptorSummary: 5-HT1/5-HT2 receptor antagonist -
B6352 α-Methyl-5-hydroxytryptamine maleateSummary: 5-HT2B receptor agonist -
B6355 PCA 4248Summary: PAF antagonist -
B6364 PRE-084 hydrochloride1 CitationTarget: Sigma ReceptorsSummary: selective σ1 receptor agonist -
B6365 MetergolineSummary: 5-HT1/5-HT2 antagonist -
B6379 4-PPBP maleateSummary: σ ligand and NR1a/2B NMDA receptors antagonist -
B6382 2-PMDQSummary: α1-adrenoceptor antagonist -
B6384 SpiroxatrineSummary: 5-HT1A antagonist and α2C adrenergic receptor antagonist -
B6397 2-MPMDQSummary: α1-adrenoceptor antagonist,potent and selective

